Medical News

RSS

New SMArT platform improves safety of CRISPR gene editing

A team of researchers led by Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) has developed a new strategy to significantly improve the precision and safety of CRISPR-Cas9 gene editing in human blood stem cells, potentially overcoming one of the major barriers limiting broader clinical application of genome editing therapies.

1 Jun 2026

Weight loss drugs could widen health inequalities without nutritional support

Drugs such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro) are transforming obesity treatment, but without affordable, healthy food and appropriate support, they could widen health inequalities in the UK, according to researchers at UCL and the University of Cambridge.

1 Jun 2026

Enhancing reproducibility in genomics workflows with magnetic bead-based extraction

In this interview, Dr Dagmara Lewandowska talks about innovations in magnetic bead-based extraction and genomics automation.

From INTEGRA Biosciences 1 Jun 2026

Remote AI algorithm reliably detects safety criteria in pediatric surgery

Laparoscopic cholecystectomy is increasingly performed in children, yet bile duct injury remains a serious and potentially devastating complication.

1 Jun 2026

Bariatric surgery improves long-term ability to manage household tasks

People who undergo bariatric surgery and see substantial weight loss are better able to cope with household tasks such as cleaning, laundry and grocery shopping.

1 Jun 2026

Laverock Therapeutics awarded in excess of £2.2 M through two innovation grants to support AI-powered platform development and to expand therapeutic programs outside of oncology

Laverock Therapeutics ('Laverock'), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced it has been awarded two new grants totaling in excess of £2.2 M to support the next generation of its gene-control platform development, and expansion into additional non-oncology therapeutics areas.

From Laverock Therapeutics 1 Jun 2026

Millions live with undiagnosed heart rhythm disorders – World Heart Rhythm Week 2026 calls for urgent action

Millions of people worldwide are living with undiagnosed heart rhythm disorders that can lead to stroke, heart failure or sudden cardiac death – often with little or no warning.

1 Jun 2026

Pharmacist-led care delivering real results for women’s health

Pharmacy Guild of Australia, NSW Branch, today welcomed the release of new data from two NSW Government-sponsored clinical trials confirming allowing pharmacists to diagnose and treat uncomplicated urinary tract infections (UTIs) and providing resupply of oral contraception is delivering safe, effective care for women, while easing pressure on the health system and saving emergency departments millions of dollars.

1 Jun 2026

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships.

From Hanson Wade Group - 4th Nasal Formulation & Delivery Summit 1 Jun 2026

Apple Watch app detects seizures with 98% accuracy

The EpiWatch app shows high sensitivity in detecting tonic-clonic seizures in children and adults, potentially reducing SUDEP risk with timely alerts.

1 Jun 2026

Health workers face hidden exposure to cancer-linked hazards

A study reveals high exposure to cancer risk factors among health and social care workers in Europe, underscoring the need for enhanced protective measures.

1 Jun 2026

Lower Alzheimer’s amyloid levels in Black and Latinx adults

Findings show lower amyloid PET positivity in Black and Latinx adults with cognitive impairment, highlighting disparities in dementia diagnosis and treatment.

1 Jun 2026

Global policy gaps slow biosimilar adoption and access

Nine out of 10 prescriptions are filled by generic drugs - FDA-approved carbon copies of brand-name drugs with expired patents.

1 Jun 2026

Online resources on AI and cancer lack quality, need improvement

Online information about artificial intelligence (AI) and its impact on cancer research and treatment for both the patient and general-public audiences is limited, and the available webpages and videos are largely of low quality, difficult to read, and frequently omit risks of AI use, according to new research presented today at the at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9000) and led by researchers from the Abramson Cancer Center (ACC) of the University of Pennsylvania and Penn's Perelman School of Medicine.

1 Jun 2026

New PET imaging tracks tumor progression and cardiac inflammation during cancer therapy

A novel PET imaging approach enables simultaneous visualization of tumor progression and cardiac inflammatory responses during cancer treatment.

1 Jun 2026

PSMA PET detects high-risk prostate cancer bone metastases

Compared to conventional imaging techniques, prostate specific membrane antigen (PSMA) PET imaging provides superior detection of bone metastases in prostate cancer patients a critical indicator of a patient's long-term survival.

1 Jun 2026

New imaging method distinguishes inflammation from lung fibrosis

A new SPECT/CT imaging approach can accurately differentiate inflammation from fibrosis in interstitial lung disease (ILD) patients, according to new research presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting.

1 Jun 2026

Justicia carnea extract alleviates oxidative stress in pancreatitis

Chronic pancreatitis is an inflammatory disease and is difficult to manage despite advancements in medical science.

1 Jun 2026

Hypoxia-gated AAV enables targeted treatment for advanced NSCLC

Adeno‑associated virus (AAV) vectors offer safety and durable expression but lack tumor specificity. This hypothesis proposes an NSCLC‑directed, hypoxia‑responsive AAV platform that integrates MGS4 peptide‑guided capsid targeting with dual hypoxia‑responsive element (HRE)‑gated promoters driving Q‑CXCL9‑Fc (chemokine) and miR‑30‑based shRNA against mesothelin (MSLN).

1 Jun 2026

Mesenchymal drift may explain how aging cells lose their identity

Mesenchymal drift may help explain how cells lose stable identity and acquire pro-fibrotic, inflammatory mesenchymal traits during aging. The review proposes MD as a unifying framework that links multiple hallmarks of aging and highlights partial reprogramming as a potential, but still preclinical, way to counteract this process.

1 Jun 2026